Sign in

Research summary ·

Comparative efficacy and safety of quetiapine versus other atypical antipsychotics for behavioral and psychological symptoms in Alzheimer's disease: a systematic review and meta-analysis.

Written based on 1 research study on PubMed, searched on 11 Nov 2026.

What was studied

This meta-analysis compared quetiapine with other atypical antipsychotics, mostly risperidone and olanzapine. The people had Alzheimer's disease with behavior and mood symptoms. The team searched PubMed, Embase and other databases up to March 15, 2024. It used only randomized trials. The main outcome was treatment failure. Safety outcomes were specific adverse events. 2143 participants were included. The aim was to compare how well they work and how safe they are.

What they found

Quetiapine had lower odds of treatment failure, at 0.66. It did better than risperidone, at 0.50. The trend versus olanzapine was not significant, at 0.90. Its risk of extrapyramidal symptoms was far lower, at 0.17. Somnolence, dizziness and constipation did not differ.

What it means for patients

The paper says quetiapine may have a possible edge in efficacy. This was mainly over risperidone. Overall, effectiveness was close to that of other atypicals. Its main feature was a lower risk of extrapyramidal symptoms.

Why it is not certain yet

The paper notes moderate bias risk in the trials. Efficacy measures had to be harmonized. Long-term safety data are scarce.

Source

Comparative efficacy and safety of quetiapine versus other atypical antipsychotics for behavioral and psychological symptoms in Alzheimer's disease: a systematic review and meta-analysis.

PubMed · PMID 43005608

We restate facts from the source record in our own words. The original wording belongs to its publisher.

This page is not medical advice. Talk to your doctor about your own care.

Back to Alzheimer disease publications